Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results From the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results From the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 7, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the Phase 3 dry eye disease clinical trial of reproxalap.
马塞诸塞州莱克星顿市——（商业线），2024年8月7日——Aldeyra Therapeutics公司（纳斯达克股票代码：ALDX）（Aldeyra）今天宣布将于2024年8月8日星期四上午9:00举行网络直播和电话会议，提供reproxalap干眼病3期临床试验的头条结果。
The dial-in numbers are (888) 596-4144 for domestic callers and (646) 968-2525 for international callers. The access code is 7321123. A live audio webcast of the conference call also will be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com.
国内拨打电话号码为（888）596-4144，国际拨打电话号码为（646）968-2525。会议代码为7321123。您还可以访问Aldeyra网站（ir.aldeyra.com）的“投资者与媒体”部分，收听电话会议的实时网络直播。
After the live webcast, the event will remain archived on Aldeyra's website for 90 days.
网络直播结束后，本次活动将会存档于 Aldeyra 网站上长达90天。
About Aldeyra
关于Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
Aldeyra Therapeutics 是一家致力于发现适用于免疫介导性和代谢性疾病的创新疗法的生物技术公司。我们的方法是开发能够调节蛋白质系统而不是直接抑制或激活单个蛋白质靶位的药物，从而达到优化多种途径的目的，同时最大限度地减少毒性。我们的产品候选药物包括 RASP（活性醛基物种）调节剂 ADX-629、ADX-248、ADX-743、ADX-631 以及化学相关分子，旨在潜在治疗系统性和视网膜免疫介导性和代谢性疾病。我们的后期产品候选药物是 reproxalap，这是一种用于潜在治疗干眼病和过敏性结膜炎的 RASP 调节剂，以及 ADX-2191，这是一种新型配方的眼内甲氨蝶呤，用于潜在治疗色素性视网膜炎。
View source version on businesswire.com:
请查看商业线(businesswire.com)的源版本。
Investor & Media:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com
投资者和媒体：
David Burke
电话：（917）618-2651
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
来源：Aldeyra Therapeutics股份有限公司
